Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | VCP | P55072 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501768 | 1.00 | KIF11 (0.44) | KIF11CHRNB4CHRNA3CA1CA2 | |
| SCHEMBL8696040 | 0.84 | CHRNB4 (0.45) | KIF11CHRNB4CHRNA3 | |
| SCHEMBL9542642 | 0.82 | RAB9A (0.39) | CHRNB4CHRNA3CA1CA2NPC1 | |
| SCHEMBL14328250 | 0.82 | RAB9A (0.39) | CHRNB4CHRNA3CA1CA2NPC1 | |
| SCHEMBL20835850 | 0.82 | CHRNB4 (0.44) | CHRNB4CHRNA3PIN1KMOVCP | |
| SCHEMBL4505854 | 0.81 | L3MBTL1 (0.43) | CA1CA2PDE4DPDE4BPGR | |
| SCHEMBL4505849 | 0.81 | L3MBTL1 (0.43) | CA1CA2PDE4DPDE4BPGR | |
| SCHEMBL2586557 | 0.80 | TRPM8 (0.46) | KIF11SLC6A3 | |
| SCHEMBL20835774 | 0.80 | KMO (0.43) | KMO | |
| SCHEMBL20835431 | 0.78 | GRM4 (0.39) | PDE4DPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953158-B1 | BICYCLIC CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | APP, BACE1, PSEN1 | KIF11 4584/4885CHRNB4 188/4885CHRNA3 136/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | KIF11 4584/4885CHRNB4 188/4885CHRNA3 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.